Acadia
  • Home
  • Contact
  • Home
  • About
    • Management Team
    • Board Of Directors
    • Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Schizophrenia – Inadequate Response
    • Major Depressive Disorder
    • Schizophrenia – Negative Symptoms
    • Rett Syndrome
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Compassionate Use
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • Sec Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Total Rewards
    • Recruiting Agencies
  • Contact
  • About
    • Management Team
    • Board Of Directors
    • Mission & Values
    • History
  • Product
  • Pipeline
    • Dementia-Related Psychosis
    • Schizophrenia – Inadequate Response
    • Major Depressive Disorder
    • Schizophrenia – Negative Symptoms
    • Rett Syndrome
  • Resources
    • Parkinson’s Disease Psychosis
    • Clinical Trials
    • Investigator Initiated Trials
    • Medical Education Grants
    • Compassionate Use
    • Scientific Publications
  • Partnering
  • Investors
    • Stock Information
    • News Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • Annual Report and Proxy
    • Information Request
    • Email Alerts
  • Media
  • Careers
    • Total Rewards
    • Recruiting Agencies

Media Center


Recent News

02/12/19ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019Printer Friendly Version
12/20/18ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019Printer Friendly Version
11/30/18ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesPrinter Friendly Version
11/27/18ACADIA Pharmaceuticals Prices Public Offering of Common StockPrinter Friendly Version
11/26/18ACADIA Pharmaceuticals Announces Proposed Public Offering of Common StockPrinter Friendly Version
2019 | 2018 | 2017 | Archive

Company Information

Annual Report


Scientific Publications

Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014).

  • COMPANY FACTS
  • ACADIA is a biopharmaceutical company focused on addressing unmet medical needs in central nervous system disorders
  • Headquartered in San Diego, California
  • R&D Center, Princeton, New Jersey
  • Stock is listed on NASDAQ: ACAD
  • Chief Executive Officer:
    Stephen R. Davis
  • Media Contact
  • Print PageRSS Feeds
  • Share
  • Privacy
  • Terms
  • Email

© ACADIA Pharmaceuticals Inc. All rights reserved.